Pharma Stocks
-
Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?
Royalty Pharma’s new royalty deal on rare blood disorder therapy Royalty Pharma (RPRX) has agreed to provide US$100 million in…
Read More » -
Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?
SHENZHEN, CHINA – JULY 27: In this photo illustration, a smartphone displays the logo of Merck & Co., Inc. (NYSE:…
Read More » -
Amneal Pharmaceuticals (AMRX) Stock Looks Fairly Valued But Earnings Still Look Rich
After a very large 3 year gain, Amneal Pharmaceuticals now trades at around US$17.90 and the valuation picture looks less…
Read More » -
Bristol Myers Squibb (BMY) Teams Up On AI Antibody Discovery Push
Bristol Myers Squibb (NYSE:BMY) has entered a new collaboration with Chai Discovery to advance AI driven therapeutic antibody discovery. The…
Read More » -
Stocks to watch: Tata Motors, Tata Power, Mankind Pharma, SBI, RailTel | Markets News
Stocks to watch today: Benchmark equity indices are likely to see a positive start on Friday, as indicated by…
Read More » -
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT) Earnings results often indicate what direction a company will take in…
Read More » -
The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift
Lexicon Pharmaceuticals, Inc. reported past second-quarter 2026 results showing revenue of US$692,000 versus US$28.87 million a year earlier, with net…
Read More » -
InnoCan Pharma Stock Under Pressure as Bearish Momentum Raises Correction and Valuation Risks
Key Highlights InnoCan Pharma shares remain under pressure as investors reassess valuation, execution risk and the timeline for pharmaceutical…
Read More » -
Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity
Christopher Hite, Executive Vice President and Chairman of Partnering at Royalty Pharma plc (NASDAQ:RPRX) RPRX (NASDAQ:RPRX) , disclosed in a…
Read More » -
Why Is Ionis Pharmaceuticals (IONS) Pushing RG-6299 Into A Pivotal Phase III Trial?
Ionis Pharmaceuticals (NasdaqGS: IONS) and partners Roche and Chugai are advancing RG-6299, an antisense therapy for IgA nephropathy, into a…
Read More »